Pashman Stein Walder Hayden is pleased to announce that Gregg H. Hilzer has been named Co-Chair of the firm’s Cannabis & Hemp Law practice, effective January 1, 2021. The elevation of Gregg caps off a successful expansion of the firm’s cannabis team in 2020 with the addition of three lateral partners, Gregg, Svetlana (Lana) Ros, Raymond M. Brown, and one associate, Rachel E. Simon.Managing Partner Michael S. Stein commented, “With the pending legalization of adult-use cannabis under New Jersey law, the firm’s Cannabis & Hemp practice is rapidly expanding. While Gregg just joined the firm as partner in fall 2020, he has extensive experience advising medical marijuana companies and assisting clients with cannabis license applications. Combining Gregg’s experience and leadership to our already strong practice led by Sean Mack will create further synergies to better serve our clients.”
In addition to cannabis and hemp law, Gregg focuses his practice on white-collar criminal investigations, complex litigation and regulatory matters.Gregg has experience advising existing medical marijuana operators and representing applicants poised to enter various aspects of the medical marijuana industry. In both the medical marijuana and hemp spaces, he provides multifaceted legal guidance to business entities and individuals focused on managing risk and ensuring compliance with regulatory requirements. Gregg’s experience also includes complex litigation matters on behalf of financial institutions, multinational corporations, public entities, small businesses, and individuals. A highly skilled litigator, he has successfully represented a wide range of clients in the state and federal courts of New Jersey and New York. He also has substantial experience representing clients before various regulators, including the New Jersey Department of Banking and Insurance, New Jersey Board of Medical Examiners, and New Jersey Office of Attorney Ethics. His white-collar experience includes defending matters involving allegations of bank, tax and healthcare fraud; commercial bribery; and violations of the False Claim Act. He is also regularly called upon to evaluate his client’s policies and procedures to ensure regulatory compliance and effective risk management.